Hemab Therapeutics (COAG) FDA Approvals $45.71 -1.84 (-3.87%) As of 03:52 PM Eastern Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Hemab Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Hemab Therapeutics (COAG). Over the past two years, Hemab Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as HMB-002. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. HMB-002 FDA Regulatory Events HMB-002 is a drug developed by Hemab Therapeutics for the following indication: in Von Willebrand disease. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Data Presentation - July 14,2026Data Presentation Drug: HMB-002Announced Date: July 14, 2026Indication: in Von Willebrand diseaseAnnouncementHemab Therapeutics today presented clinical and preclinical data from sutacimig in GT and FVIID at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France. This follows the presentation of new clinical data from HMB-002 in Von Willebrand disease and the announcement of the HMB-003 program on Sunday, July 12.AI SummaryHemab Therapeutics presented new clinical and preclinical data on sutacimig at the ISTH 2026 Congress in Paris. In people with Glanzmann thrombasthenia (GT), Phase 2 long-term extension results showed that sutacimig continued to reduce bleeding over time, with safety and tolerability that were manageable. The company said it plans to start a Phase 3 trial in the second half of 2026 using an agreed weekly dosing schedule. Preclinical findings also showed sutacimig restored thrombin generation in Factor VII deficiency, even under disease-like conditions, supporting its possible use as a broad hemostatic treatment. In separate GT natural history studies, researchers confirmed that bleeding can be a lifelong burden and that preventive therapy is still underused, highlighting the need for better prophylaxis. The congress featured nine Hemab presentations in total, including data on HMB-002 and the HMB-003 program.Read Announcement Hemab Therapeutics FDA Events - Frequently Asked Questions Has Hemab Therapeutics received FDA approval? As of now, Hemab Therapeutics (COAG) has not received any FDA approvals for its therapy in the last two years. What drugs has Hemab Therapeutics submitted to the FDA? In the past two years, Hemab Therapeutics (COAG) has reported FDA regulatory activity for HMB-002. What is the most recent FDA event for Hemab Therapeutics? The most recent FDA-related event for Hemab Therapeutics occurred on July 14, 2026, involving HMB-002. The update was categorized as "Data Presentation," with the company reporting: "Hemab Therapeutics today presented clinical and preclinical data from sutacimig in GT and FVIID at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France. This follows the presentation of new clinical data from HMB-002 in Von Willebrand disease and the announcement of the HMB-003 program on Sunday, July 12." What conditions do Hemab Therapeutics' current drugs treat? Currently, Hemab Therapeutics has one therapy (HMB-002) targeting the following condition: in Von Willebrand disease. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Acurx Pharmaceuticals FDA EventsAkebia Therapeutics FDA EventsAltimmune FDA EventsEstrella Immunopharma FDA EventsNiagen Bioscience FDA EventsOmeros FDA EventsOSR FDA EventsRocket Pharmaceuticals FDA EventsTonix Pharmaceuticals FDA EventsZai Lab FDA EventsEli Lilly and Company FDA EventsClearPoint Neuro FDA EventsMoleculin Biotech FDA EventsAprea Therapeutics FDA EventsCapricor Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Crinetics Pharmaceuticals FDA Events Protagonist Therapeutics FDA Events TG Therapeutics FDA Events Qiagen FDA Events Apogee Therapeutics FDA Events Immunovant FDA Events Vaxcyte FDA Events Rhythm Pharmaceuticals FDA Events Mirum Pharmaceuticals FDA Events Lantheus FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:COAG last updated on 7/14/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemab Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemab Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Data Presentation - July 14,2026Data Presentation Drug: HMB-002Announced Date: July 14, 2026Indication: in Von Willebrand diseaseAnnouncementHemab Therapeutics today presented clinical and preclinical data from sutacimig in GT and FVIID at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France. This follows the presentation of new clinical data from HMB-002 in Von Willebrand disease and the announcement of the HMB-003 program on Sunday, July 12.AI SummaryHemab Therapeutics presented new clinical and preclinical data on sutacimig at the ISTH 2026 Congress in Paris. In people with Glanzmann thrombasthenia (GT), Phase 2 long-term extension results showed that sutacimig continued to reduce bleeding over time, with safety and tolerability that were manageable. The company said it plans to start a Phase 3 trial in the second half of 2026 using an agreed weekly dosing schedule. Preclinical findings also showed sutacimig restored thrombin generation in Factor VII deficiency, even under disease-like conditions, supporting its possible use as a broad hemostatic treatment. In separate GT natural history studies, researchers confirmed that bleeding can be a lifelong burden and that preventive therapy is still underused, highlighting the need for better prophylaxis. The congress featured nine Hemab presentations in total, including data on HMB-002 and the HMB-003 program.Read Announcement
